These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 9886578)

  • 1. Meloxicam inhibits the growth of colorectal cancer cells.
    Goldman AP; Williams CS; Sheng H; Lamps LW; Williams VP; Pairet M; Morrow JD; DuBois RN
    Carcinogenesis; 1998 Dec; 19(12):2195-9. PubMed ID: 9886578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meloxicam inhibits the growth of non-small cell lung cancer.
    Tsubouchi Y; Mukai S; Kawahito Y; Yamada R; Kohno M; Inoue K; Sano H
    Anticancer Res; 2000; 20(5A):2867-72. PubMed ID: 11062695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meloxicam inhibits prostaglandin E(2) generation via cyclooxygenase 2 in the inflammatory site but not that via cyclooxygenase 1 in the stomach.
    Ogino K; Hatanaka K; Kawamura M; Ohno T; Harada Y
    Pharmacology; 2000 Nov; 61(4):244-50. PubMed ID: 11093076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1.
    Ogino K; Hatanaka K; Kawamura M; Katori M; Harada Y
    Pharmacology; 1997 Jul; 55(1):44-53. PubMed ID: 9309800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2.
    Sheng H; Shao J; Kirkland SC; Isakson P; Coffey RJ; Morrow J; Beauchamp RD; DuBois RN
    J Clin Invest; 1997 May; 99(9):2254-9. PubMed ID: 9151799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sulindac sulfide, but not sulindac sulfone, inhibits colorectal cancer growth.
    Williams CS; Goldman AP; Sheng H; Morrow JD; DuBois RN
    Neoplasia; 1999 Jun; 1(2):170-6. PubMed ID: 10933052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
    Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.
    Richter M; Weiss M; Weinberger I; Fürstenberger G; Marian B
    Carcinogenesis; 2001 Jan; 22(1):17-25. PubMed ID: 11159736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
    Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M
    Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
    J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.
    Zweifel BS; Davis TW; Ornberg RL; Masferrer JL
    Cancer Res; 2002 Nov; 62(22):6706-11. PubMed ID: 12438270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings.
    Engelhardt G; Bögel R; Schnitzer C; Utzmann R
    Biochem Pharmacol; 1996 Jan; 51(1):21-8. PubMed ID: 8534264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
    Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
    Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions.
    Wardlaw SA; March TH; Belinsky SA
    Carcinogenesis; 2000 Jul; 21(7):1371-7. PubMed ID: 10874016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of oxicam inhibitors of cyclooxygenase on oxidative stress generation in rat gastric mucosa. A comparative study.
    Villegas I; Martín MJ; La Casa C; Motilva V; De La Lastra CA
    Free Radic Res; 2002 Jul; 36(7):769-77. PubMed ID: 12180128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
    Kay-Mugford P; Benn SJ; LaMarre J; Conlon P
    Am J Vet Res; 2000 Jul; 61(7):802-10. PubMed ID: 10895904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 regulates granulocyte-macrophage colony-stimulating factor, but not interleukin-8, production by human vascular cells: role of cAMP.
    Stanford SJ; Pepper JR; Mitchell JA
    Arterioscler Thromb Vasc Biol; 2000 Mar; 20(3):677-82. PubMed ID: 10712390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [COX-2 inhibition: latest on NSAID].
    Z Orthop Ihre Grenzgeb; 1997; 135(1):Oa20-1. PubMed ID: 9199064
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
    Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
    Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
    Sheng H; Shao J; Morrow JD; Beauchamp RD; DuBois RN
    Cancer Res; 1998 Jan; 58(2):362-6. PubMed ID: 9443418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.